Form 4: Lemaitre Vascular Director Reports Acquisition of Dividend Equivalent Rights

Lemaitre Vascular Inc. Director John James O'Connor reported the acquisition of additional dividend equivalent rights tied to previously granted equity awards.

Summary

• John James O'Connor, a Director of Lemaitre Vascular Inc. (LMAT), filed a Form 4 reporting changes in beneficial ownership.
• On May 29, 2025, Mr. O'Connor acquired a total of 3.9089 Dividend Equivalent Rights (DERs) across five separate transactions.
• These DERs accrued on existing Restricted Stock Unit (RSU) awards granted on December 12, 2022, December 8, 2023, and December 6, 2024.
• Additionally, DERs accrued on Performance Share Unit (PSU) awards granted on December 12, 2022, and December 8, 2023.
• Each dividend equivalent right is the economic equivalent of one share of Lemaitre Vascular's common stock and vests proportionately with its underlying award.
• The reported price for these acquisitions was $0, as they represent accrued dividends on existing equity awards rather than new purchases.

Sentiment

Score: 5

Explanation: The document is a routine insider transaction report detailing the accrual of dividend equivalent rights on existing equity awards. It does not contain information that would significantly alter the company's financial outlook or operational status, thus indicating a neutral sentiment.

Positives

• The acquisition of Dividend Equivalent Rights indicates that the director's existing equity awards are accruing value, aligning management's interests with shareholder returns through dividends.
• The vesting of these rights proportionately with the underlying RSU and PSU awards suggests a long-term commitment and retention mechanism for the director.

Future Outlook

This Form 4 filing is a historical report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, reporting changes in beneficial ownership by insiders. The accrual of Dividend Equivalent Rights on equity awards is a common component of executive and director compensation packages, designed to align their interests with shareholders by providing them with the economic benefit of dividends paid on underlying shares before the awards fully vest.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Share Units (PSUs) with accruing Dividend Equivalent Rights is a standard practice in executive compensation across various industries, including the medical device sector where Lemaitre Vascular operates.
• This compensation structure is comparable to those seen in other publicly traded companies that aim to incentivize long-term performance and retention of key personnel by linking their compensation to both stock price appreciation and dividend distributions.

Related Party Transactions

• The transaction involves a director of Lemaitre Vascular Inc. acquiring Dividend Equivalent Rights, which is a form of compensation and a routine related-party transaction within the scope of corporate governance.

Stakeholder Impact

• Shareholders: The accrual of Dividend Equivalent Rights aligns the director's interests with shareholders, as these rights are tied to the company's common stock and its dividend policy. This can be viewed positively as it encourages long-term value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Key Dates

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Director Compensation, Equity Awards